Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer).

Tahlia ScheinbergJames KenchMartin StocklerKate L MahonLucille SebastianPhillip StrickerAnthony M JoshuaH WooRuban ThanigasalamNariman AhmadiMargaret M CenteneraLisa M ButlerLisa G Horvath

Published in: BMJ open (2020)

2.0, 30 May 2019 TRIAL REGISTRATION NUMBER: Australian New Zealand Clinical Trials Registry (ACTRN12618000354280).

Keyphrases

prostate cancer
clinical trial
radical prostatectomy
study protocol
phase ii
phase iii